×
About 5,265 results

ALLMedicine™ Angioedema Center

Research & Reviews  1,302 results

Isolated tongue angioedema after alteplase infusion in acute ischemic stroke.
https://doi.org/10.2174/1574886316666210728104331
Current Drug Safety; Pisani E, Gaudiano C et. al.

Jul 30th, 2021 - Angioedema, like anaphylaxis, has been reported as a rare adverse event of alteplase infusion in acute ischemic stroke. We report the case of a patient with acute ischemic stroke who after treatment of alteplase developed angioedema. We report the...

Pediatric Allergy: An Overview.
https://doi.org/10.1016/j.pop.2021.04.006
Primary Care; Rajaee A, Masquelin ME et. al.

Jul 28th, 2021 - Allergy is a broad topic encompassing common clinical allergic diseases, asthma, and complex immunodeficiencies. In this article, the authors discuss the most common allergic diseases and anaphylaxis and briefly review the current knowledge and ma...

Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined Wi...
https://doi.org/10.1161/HYPERTENSIONAHA.121.17041
Hypertension (Dallas, Tex. : 1979); Alves-Lopes R, Montezano AC et. al.

Jul 27th, 2021 - Combined inhibition of NEP (neutral endopeptidase) and ACE (angiotensin-converting enzyme), without unwanted effects, remains an attractive therapeutic strategy in cardiovascular medicine. Omapatrilat, a dual NEP inhibitor-ACE inhibitor, was a pro...

Demographic and clinical characteristics of patients with hereditary angioedema in Canada.
https://doi.org/10.1016/j.anai.2021.07.015
Annals of Allergy, Asthma & Immunology : Official Publica... Lee EY, Hsieh J et. al.

Jul 24th, 2021 - Data on the clinical and demographic features of Canadian patients with hereditary angioedema (HAE) is lacking. Herein, we describe these important features in a large Canadian HAE cohort and compare our patients to HAE patients in other countries...

Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE St...
https://doi.org/10.1111/all.15011
Allergy Banerji A, Bernstein JA et. al.

Jul 22nd, 2021 - The aim was to evaluate long-term effectiveness and safety of lanadelumab in patients ≥12y old with hereditary angioedema (HAE) 1/2 (NCT02741596). Rollover patients completing the HELP Study and continuing into HELP OLE received one lanadelumab 30...

see more →

Guidelines  4 results

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.

Jan 11th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

A consensus parameter for the evaluation and management of angioedema in the emergency ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100605
Academic Emergency Medicine : Official Journal of the Soc... Moellman JJ, Bernstein JA et. al.

Apr 16th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, an...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.

Jun 4th, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

International consensus and practical guidelines on the gynecologic and obstetric manag...
https://doi.org/10.1016/j.jaci.2011.11.025
The Journal of Allergy and Clinical Immunology; Caballero T, Farkas H et. al.

Dec 27th, 2011 - There are a limited number of publications on the management of gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH). We sought to elaborate guidelines for optimizing the managem...

see more →

Drugs  574 results see all →

Clinicaltrials.gov  58 results

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
https://clinicaltrials.gov/ct2/show/NCT03712228

Apr 22nd, 2020 - This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.

Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.
https://clinicaltrials.gov/ct2/show/NCT03296358

Feb 11th, 2020 - Research Methodology Target Population Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as eruption of wheals, central swelling of various...

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
https://clinicaltrials.gov/ct2/show/NCT01386658

Nov 20th, 2019 - Study HGT-FIR-086 will enroll 30 subjects from 2 to less than 18 years of age, divided into 2 groups: prepubertal and pubertal/postpubertal. At least 10 prepubertal children and at least 20 adolescents (including 10 treated during a HAE attack) mu...

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
https://clinicaltrials.gov/ct2/show/NCT03240133

Jul 10th, 2019 - This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with...

see more →

News  162 results

FDA Approves Myrbetriq to Treat Pediatric NDO
https://www.medscape.com/viewarticle/948305

Mar 29th, 2021 - The US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurologic impairment, in children aged 3 years a...

FDA Approvals, Highlights, and Summaries
https://reference.medscape.com/viewarticle/945186

Feb 24th, 2021 - Allergy/Immunology Orladeyo (berotralstat) Berotralstat is the first oral kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 years and older. Kallikrein is a protease that cleaves high-molecula...

Fast Five Quiz: Food Allergies
https://reference.staging.medscape.com/viewarticle/936716_3

Sep 8th, 2020 - Although anaphylaxis can occur without skin symptoms, cutaneous reactions are the most common clinical manifestations of an allergic reaction to a food or food additive. Peanuts remain the most common cause of severe food allergy symptoms and anap...

For Patients with HFrEF, What Is the Role for and Treatment Pearls for ARNI?
https://decisionpoint.medscape.com/cardiology/viewarticle/926451

May 21st, 2020 - This transcript has been edited for clarity. The data with angiotensin receptor neprilysin inhibitor (ARNI) therapy, valsartan sacubitril, continue to evolve in terms of its role in the patient’s management with heart failure reduced ejection frac...

Simple Decision Rule Helps Identify People at Low-Risk for Penicillin Allergy
https://www.staging.medscape.com/viewarticle/926960

Mar 18th, 2020 - NEW YORK (Reuters Health) - A simple clinical decision rule for penicillin allergy can help doctors and antimicrobial-stewardship programs identify people at low-risk of penicillin allergy at the point of care, report doctors from Australia who de...

see more →

Patient Education  6 results see all →